Alexion Overview

  • Founded

  • 1992

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 3,981

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $41.1B

Alexion General Information

Description

Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating conditions. The company is involved in biotechnology research and offers therapies that treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) among others, enabling individuals to overcome the issues they face every day.

Contact Information

Website
www.alexion.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
AstraZeneca
Primary Office
  • 121 Seaport Boulevard
  • Boston, MA 02210
  • United States
+1 (475) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alexion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 21-Jul-2021 $41.1B 000.00 Completed Profitable
6. Merger/Acquisition 06-Dec-2019 Cancelled Profitable
5. PIPE 10-Mar-2018 Completed Profitable
4. PIPE 06-Aug-2017 Completed Profitable
3. 2PO 23-May-2012 00000 Completed Profitable
2. IPO 28-Feb-1996 Completed Profitable
1. Early Stage VC 01-Jan-1994 Completed Product Development
To view Alexion’s complete valuation and funding history, request access »

Alexion Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating
Drug Discovery
Boston, MA
3,981 As of 2022
00.00 0000-00-00
000000&0

000000

t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000000000000
San Diego, CA
000 As of 0000
00000
0000 0000-00-00
000000&0

000000

lit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidat
000000000000000
Mountain View, CA
000 As of 0000
00000
0.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alexion Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prometheus Laboratories Formerly VC-backed San Diego, CA 000 00000 000000&0
000000000000 Formerly VC-backed Mountain View, CA 000 00000 000000&0 00000
0000000 Formerly VC-backed San Diego, CA 000 00000 000000&0 00000
000000 Corporation Malvern, PA 00 000.00 000000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 48 competitors. Get the full list »

Alexion Patents

  • 1,867

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 115

    Granted

  • 63

    Pending

  • 000

    Expiring in next 12 mo

Alexion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021364779-A1 Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase Pending 21-Oct-2021
CA-3178003-A1 Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors Pending 20-Aug-2021
CA-3177998-A1 Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor Pending 20-Aug-2021
CA-3177165-A1 Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) Pending 14-Jun-2021
US-20220399087-A1 Method and system for improved management of genetic diseases Pending 11-Jun-2021 G16H20/10
To view Alexion’s complete patent history, request access »

Alexion Executive Team (47)

Name Title Board Seat Contact Info
Sean Christie Chief Financial Officer & Administrative Officer
Daniel Bazarko Senior Vice President, Finance & Chief Accounting Officer
John Orloff MD Executive Vice President & Head of Research & Development
Scott Weintraub Vice President, Global Marketing & Head of Global Commercial Strategy
Venu Nagali Vice President, Finance and Value Creation
You’re viewing 5 of 47 executive team members. Get the full list »

Alexion Board Members (13)

Name Representing Role Since
John Mollen Self Board Member & Chairman of Leadership and Compensation Committee 000 0000
You’re viewing 1 of 13 board members. Get the full list »

Alexion Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alexion Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alkeon Capital Management Hedge Fund Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
BMO Financial Group Lender/Debt Provider Minority 000 0000 000000 0
Bank of the West Corporation Minority 000 0000 000000 0
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Alexion Investments & Acquisitions (25)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 16-Nov-2022 0000000000 0000 Biotechnology 0000 0000
000000 000000 06-Oct-2021 0000000000 00000 Biotechnology
000000 000000 01-Feb-2021 000000000 000.00 Buildings and Property 00000000
0000000 00000 02-Jul-2020 0000000000 00.000 Pharmaceuticals 000000 00
Achillion 28-Jan-2020 Merger/Acquisition 00.000 Pharmaceuticals 000000 00
You’re viewing 5 of 25 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Alexion Subsidiaries (3)

Company Name Industry Location Founded
Caelum Biosciences Biotechnology Bordentown, NJ 2015
0000000000 000000 Drug Discovery Amsterdam, Netherlands 0000
000000000 Drug Discovery Milford, MA 0000
To view Alexion’s complete subsidiaries history, request access »

Alexion Exits (4)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000000000 09-Sep-2019 0000 0000 Completed
  • 0000000
0000000 0000000000 05-Jan-2015 00000 00000 00 00000 Completed
  • 10 buyers
0000000 0000000000 22-Jan-2014 00000 00000 00 00000 Completed
  • 4 buyers
PhaseRx 02-Oct-2013 Convertible Debt 00.00 Completed
To view Alexion’s complete exits history, request access »